Compare SQNS & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | ONCY |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Semiconductors | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.3M | 94.0M |
| IPO Year | N/A | N/A |
| Metric | SQNS | ONCY |
|---|---|---|
| Price | $3.06 | $0.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $20.33 | $6.00 |
| AVG Volume (30 Days) | 260.1K | ★ 2.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.97 | $0.33 |
| 52 Week High | $58.30 | $1.51 |
| Indicator | SQNS | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 30.36 | 50.38 |
| Support Level | $3.01 | $0.79 |
| Resistance Level | $3.81 | $1.10 |
| Average True Range (ATR) | 0.39 | 0.11 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 4.39 | 48.58 |
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.